CCR10 and asthma: Provided that it will be feasible to ex vivo expand CCR10+ ILC2s under the stable maintenance of their functional properties, it can thus be assumed that asthma patients might benefit from the adoptive transfer and the subsequent intended pulmonary enrichment of these suppressive ILC2s.